Given that newly developed RIPK1 inhibitors have shown very limited success in clinical trials for inflammatory and neurological diseases in recent years, and that none of these inhibitors has yet reached clinical utilization, our data strongly recommend a clinical study to evaluate the already approved drug primidone for the treatment of patients suffering from psoriasis within the context of drug repurposing. The gene discussed is RIPK1; the disease is psoriasis.